



RECEIVED
CENTRAL FAX CENTER
JUN 11 2008

Fax☐ Urgent☐ Return reply requested☐ Original will be sent as confirmation

To: United States Patent and Trademark
Office

Date: June 11, 2008

Attention: Examiner Young J. Kim

Re: Appl. No. 10/602,045; Filed: June 24, 2003

From: Daniel J. Nevriy *DJN*
Reg. No. 59,118

For: **Molecular Detection Systems**
Utilizing Reiterative Oligonucleotide
Synthesis
Inventor: Michelle M. Hanna

Pages (including cover sheet): 4

Fax No: (571) 273-0785

Our Reference: 2072.0010003/MAC/DJN

Message

1. SKGF Cover Letter;
2. Credit Card Payment Form (PTO-2038) in the amount of \$130.00 to cover the Terminal Disclaimer fee under 37 C.F.R. § 1.20(d);
3. Terminal Disclaimer to Obviate a Double Patenting Rejection over a "Prior" Patent; and
4. Terminal Disclaimer to Obviate a Provisional Double Patenting Rejection Over a Pending "Reference" Application.

Certification of Facsimile Transmission

I hereby certify that this paper is being facsimile transmitted
to the Patent and Trademark Office on the date shown below.

Dana Bennett Jackson
Name

June 11, 2008
Date

832373_1.DOC

If any portion of this transmission is not received clearly or in full,
contact us at 202.371.2600 or f 202.371.2540

This message is intended for the exclusive use of the individual or entity to which it is addressed. The message may contain information that is privileged, confidential, or otherwise exempt from disclosure under applicable law. If the reader of this message is not the intended recipient, you are hereby notified that any dissemination, distribution, copying or use of this communication in any way is strictly prohibited. If you have received this communication in error, please call us collect immediately, and return the original message to us at the above address via the U.S. Postal Service.

Sterne, Kessler, Goldstein & Fox P.L.L.C. : 1100 New York Avenue, NW : Washington, DC 20005 : 202.371.2600 f 202.371.2540 : www.skgf.com

JUN 11 2008



Robert Greene Sterne
Jorge A. Goldstein
David K.S. Coroweth
Robert W. Esmond
Tracy-Gene G. Durkin
Michael A. Cambala
Michael B. Ray
Robert E. Sokohl
Eric K. Steffe
Michael Q. Lee
John M. Coveit
Robert C. Millanig
Donald J. Featherstone
Timothy J. Shea, Jr.
Michael V. Messinger
Judith U. Kim
Jeffrey T. Helvey
Edward L. Ellison
Donald R. Banowitz

Peter A. Izdman
Belen I. Del Buono
Mark Fox Evans
Vincent L. Caputo
Elizabeth J. Haas
Michael D. Specht
Kevin W. McCabe
Glenn J. Perry
Theodore A. Wood
Edward W. Yee
Grant E. Reed
Jason D. Eisenberg
Tracy L. Miller
Jon E. Vinyer
LuAnne M. DeSantis
Helene C. Carlson
Cynthia M. Bouchez
Timothy A. Doyle
Gaby L. Longworth

Lori A. Gordon
Laura A. Vogel
Badr M.S. Ali
Shannon A. Carroll
Anbar E. Khal
Michelle K. Holoubek
Marsha A. Rose
Scott A. Schaller
Lei Zhou
W. Blake Coblenz
James J. Pohl
John T. Haran
Mark W. Rygiel
Michael R. Malek
Carla A-Gun Kim
Doyle A. Stever
Ulrike Winkler Jenks
Paul A. Calvo
C. Matthew Rostler

Randall K. Balchwin
Daniel J. Newby
Lori M. Brandes
Jeffrey K. Miller
Mita Muthuraj
Scott M. Woodhouse
Christian A. Canvace
Richard D. Collier III
Keitha Hyton-Rodit
Brenda Nimmerga-Combs
Alyssa K. Sandrover
Jonathan M. Stang
Brian P. Weerakoon

Registered Patent Agents
Karen R. Markowicz
Matthew J. Dowd
Peter A. Sacarias
Danielle L. Lesting

Steven C. Oppenheimer
Aaron S. Lukas
Gaurav Ashana
Stephanie L. Elmer
Robert E. Balch
Salvador M. Bezos
Yasser Mourada

Of Counsel
Edward J. Kessler
Kenneth C. Bass III
Marvin C. Guthrie
Christopher P. Wrist
David C. Isaacson

*Admitted only in Maryland
*Admitted only in Virginia
*Practice Limited to
Federal Agencies

June 11, 2008

WRITER'S DIRECT NUMBER:
(202) 772-8658

INTERNET ADDRESS:
DNEVRIVY@SKGF.COM

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

Art Unit 1637
Via Facsimile
Attn: Mail Stop Amendment

Re: U.S. Utility Patent Application
Application No. 10/602,045; Filed: June 24, 2003
For: **Molecular Detection Systems Utilizing
Reiterative Oligonucleotide Synthesis**
Inventor: Michelle M. Hanna
Our Ref: 2072.0010003/MAC/DJN

Sir:

Transmitted herewith for appropriate action are the following documents:


1. Credit Card Payment Form (PTO-2038) in the amount of \$130.00 to cover the Terminal Disclaimer fee under 37 C.F.R. § 1.20(d);
2. Terminal Disclaimer to Obviate a Double Patenting Rejection Over a "Prior" Patent; and
3. Terminal Disclaimer to Obviate a Provisional Double Patenting Rejection Over a Pending "Reference" Application.

In the event that extensions of time are necessary to prevent abandonment of this patent application, then such extensions of time are hereby petitioned.

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.


Daniel J. Nevriy
Agent for Applicant
Registration No. 59,118

MAC/DJN:dbj
Enclosures

832367_1.DOC

Sterne, Kessler, Goldstein & Fox P.L.L.C. : 1100 New York Avenue, NW : Washington, DC 20005 : 202.371.2600 f 202.371.2540 : www.skqf.com

PAGE 2/5 * RCVD AT 6/11/2008 12:19:08 PM [Eastern Daylight Time] * SVR:USPTO-EFXXF-6/37 * DNIS:2730785 * CSID:202 371 2540 * DURATION (mm:ss):01:20

RECEIVED
CENTRAL FAX CENTER

JUN 11 2008

PTO/SB/26 (01-08)

Approved for use through 03/31/2008. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1996, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

**TERMINAL DISCLAIMER TO OBTAIN A DOUBLE PATENTING
REJECTION OVER A "PRIOR" PATENT**

Docket Number (Optional)

2072.0010003/MAC/DIN

In re Application of: **Michelle M. Hanna**Application No.: **10/602,045**Filed: **June 24, 2003**For: **Molecular Detection Systems Utilizing Reiterative Oligonucleotide Synthesis**

The owner, Ribomed Biotechnologies, Inc., of 100 percent interest in the instant application hereby disclaims, except as provided below, the terminal part of the statutory term of any patent granted on the instant application which would extend beyond the expiration date of the full statutory term prior patent No. 7,226,738 as the term of said prior patent is defined in 35 U.S.C. 154 and 173, and as the term of said prior patent is presently shortened by any terminal disclaimer. The owner hereby agrees that any patent so granted on the instant application shall be enforceable only for and during such period that it and the prior patent are commonly owned. This agreement runs with any patent granted on the instant application and is binding upon the grantee, its successors or assigns.

In making the above disclaimer, the owner does not disclaim the terminal part of the term of any patent granted on the instant application that would extend to the expiration date of the full statutory term as defined in 35 U.S.C. 154 and 173 of the prior patent, "as the term of said prior patent is presently shortened by any terminal disclaimer," in the event that said prior patent later:

expires for failure to pay a maintenance fee;

is held unenforceable;

is found invalid by a court of competent jurisdiction;

is statutorily disclaimed in whole or terminally disclaimed under 37 CFR 1.321;

has all claims canceled by a reexamination certificate;

is reissued; or

is in any manner terminated prior to the expiration of its full statutory term as presently shortened by any terminal disclaimer.

Check either box 1 or 2 below, if appropriate.

1. ☐ For submissions on behalf of a business/organization (e.g., corporation, partnership, university, government agency, etc.), the undersigned is empowered to act on behalf of the business/organization.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

2. ☒ The undersigned is an attorney or agent of record. Reg. No. 59,118


Signature

6/11/2008
Date

Daniel J. Nevriy

Typed or printed name

(202) 371-2600

Telephone Number

- ☒ Terminal disclaimer fee under 37 CFR 1.20(d) included.

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

*Statement under 37 CFR 3.73(b) is required if terminal disclaimer is signed by the assignee (owner).
Form PTO/SB/96 may be used for making this certification. See MPEP § 324.

This collection of information is required by 37 CFR 1.321. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

832,368